Evidence map›Paper›PMID 40234291›Full record

ReviewMolecular neurobiology2025

Functionalized Nanoparticles: A Promising Approach for Effective Management of Alzheimer's Disease.

Subhasri Bogadi, Mahendran Bhaskaran, Vishnuvardh Ravichandran, Jerry Nesamony, Selvam Chelliah, Gowthamarajan Kuppusamy, Gowrav Mysore Prakash, Veera Venkata Satyanarayana Reddy Karri, Samir Mallick, Farha Farahim and 3 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Subhasri BogadiDepartment of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, OotyNilgiris, Tamil Nadu, India.
Mahendran BhaskaranCollege of Pharmacy and Pharmaceutical Sciences, University of Toledo HSC, 3000 Arlington Avenue, Toledo, OH, 43614, USA. naren.mahe@gmail.com.
Vishnuvardh RavichandranDepartment of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru, India.
Jerry NesamonyCollege of Pharmacy and Pharmaceutical Sciences, University of Toledo HSC, 3000 Arlington Avenue, Toledo, OH, 43614, USA.
Selvam ChelliahCollege of Pharmacy and Health Sciences, Texas Southern University, Houston, TX- 77004, USA.
Gowthamarajan KuppusamyDepartment of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, OotyNilgiris, Tamil Nadu, India.
Gowrav Mysore PrakashDepartment of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, OotyNilgiris, Tamil Nadu, India.
Veera Venkata Satyanarayana Reddy KarriDepartment of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, OotyNilgiris, Tamil Nadu, India.
Samir MallickTennessee State University, Chemistry department, 3500 John A Merritt Blvd, Nashville, TN, 37209, USA.
Farha FarahimDepartment of Nursing, King Khalid University, Abha, 61413, Kingdom of Saudi Arabia.
Talat AliDepartment of Basic Medical Sciences, King Khalid University, Abha, 61413, Kingdom of Saudi Arabia.
Dharmavarapu Ramanadh BabuScientific Writer II at BMS Hyderabad, Hyderabad, - 500001, India.
Vetriselvan SubramaniyanDepartment of Pharmacology, Jeffrey Cheah School of Medicine and Health Sciences MONASH University, Subang Jaya, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The severe neurodegenerative disease known as Alzheimer's disease (AD) is typified by a progressive loss of memory and cognitive function. The prevalence of AD is rising due to an aging global population, calling for novel treatment strategies. A potential treatment option for AD that shows promise is the use of functionalized nanoparticles (NPs). Recent developments in the synthesis, design, and use of functionalized NPs in AD therapy are examined in this review. An outline of the pathophysiological mechanisms underlying AD is given in the first section, focusing on the roles played by tau protein aggregates and amyloid-beta plaques in the development of the illness. We then explore the many approaches used to functionalize NPs, such as surface alterations and bioconjugation methods, which enable accurate drug administration, targeted delivery, and enhanced biocompatibility. The review also emphasizes the therapeutic potential of functionalized NPs, highlighting their capacity to improve neuroprotection, lower amyloid-beta aggregation, and improve blood-brain barrier penetration. The potential of NPs as a tool for disease modification and symptom relief is highlighted by recent pre-clinical and clinical research. Concerns about toxicity and safety are also covered, underscoring the significance of thorough testing and the field's future directions. Functionalized NPs have great promise as a multimodal strategy to treat AD, offering patients hope for better quality of life, early diagnosis, and efficient disease treatment. This study highlights the growing role of nanotechnology in the search for novel and potent therapies for AD.

Indexed as

Alzheimer DiseaseNanoparticlesAmyloid beta-PeptidesAnimalsBlood-Brain BarrierDrug Delivery SystemsHumanstau ProteinsAmyloid beta-Peptidestau ProteinsAlzheimer’s diseaseBlood–brain barrierEffective managementMolecular mechanismsNanoparticles

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.